Screener
Kymera Therapeutics KYMR Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses (Note 8) | 48,476 | 42,274 |
| Deferred revenue | — | 22,925 |
| Operating lease liabilities | 12,119 | 11,941 |
| Finance lease liabilities | 1,577 | 1,815 |
| Other current liabilities | 236 | 242 |
| Total current liabilities | $71,326 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's current debt?
- Kymera Therapeutics (KYMR) reported current debt of $1.58M in Q2 2026.
- How has Kymera Therapeutics's current debt changed year-over-year?
- Kymera Therapeutics's current debt decreased by 17.0% year-over-year, from $1.9M to $1.58M.
- What is the long-term trend for Kymera Therapeutics's current debt?
- Over 5 years (2020 to 2025), Kymera Therapeutics's current debt has grown at a 21.4% compound annual growth rate (CAGR), from $689K to $1.82M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Kymera Therapeutics's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude